目前,HER2 低表 达乳腺癌的生物学特征尚不十分明确,HER2 低表达与 HER2 零表达患者预后以及传统治疗 反应差异亦不明确。该研究旨在明确 HER2 低表达与 HER2 零表达早期乳腺癌(eBC)患者 新辅助化疗(NAC)后的化疗敏感性和长期预后。 研...
Relative Breast Cancer Survival Rate by Age 11 min read If you’ve been diagnosed withbreast cancer, your focus will be on getting the right treatment, but you’ll wonder, too, about your chances of surviving. Your doctor may call this your prognosis. It’s an estimate of how the disease...
BRCA1/2 mutations occurred in 6.6% of patients with human epidermal growth factor receptor 2 (HER2/neu)‐positive breast cancer. However, BRCA mutation status did not affect survival outcomes in patients who had HER2/neu‐positive breast cancer....
[2] Erika P. Hamilton, Sara A. Hurvitz, Seock-Ah Im, et al., Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. JCO 42, 1025-1025(2024). DOI:10.1200/JCO.2024.42...
在接受新辅助化疗的早期乳腺癌患者中,HER2低表达与HER2零表达患者化疗敏感性或预 后无明显差异。提示目前乳腺癌NAC时,无需单独考虑HER2低表达或HER2零表达状态。 参考文献 Ilie SM, Briot N, Constantin G, Roussot N, Ilie A, Bergeron A, Arnould L, Beltjens F, Desmoulin I, Mayeur D, Kaderbhai C...
SPSS (v15) was used to plot Kaplan–Meier survival curves using breast cancer-specific death as an outcome endpoint (log-rank testing). Cox regression analysis was carried out to evaluate the independence of HER2 in predicting the outcome in conjunction with age, oestrogen receptor (ER), grade...
在接受新辅助化疗的早期乳腺癌患者中,HER2低表达与HER2零表达患者化疗敏感性或预 后无明显差异。提示目前乳腺癌NAC时,无需单独考虑HER2低表达或HER2零表达状态。 参考文献 Ilie SM, Briot N, Constantin G, Roussot N, Ilie A, Bergeron A, Arnould L, Beltjens F, Desmoulin I, Mayeur D, Kaderbhai C...
Breast cancer (BRCA) has a high incidence and mortality rate among women. Different molecular subtypes of breast cancer have different prognoses and require personalized therapies. It is imperative to find novel therapeutic targets for different molecular subtypes of BRCA. Here, we demonstrated for the...
In general, breast cancer has different molecular players of the cellular matrix cross-talk that control growth, survival, and response to treatment (54). HER2 expression is known to correlate with the overexpression of VEGF, which is one of the angiogenesis stimulator (55). DWI measures the ...
Median overall survival since initial diagnosis of metastasis was 34 months (0-277+). Conclusion: It could be shown that, compared to historical controls, targeted therapy against HER2 prolongs overall survival of patients with HER2-positive metastatic breast cancer who receive treatment in routine ...